Associations Between Baseline Severity and Treatment Effects in Digital Interventions for Eating Disorders: A Meta-Regression.

Eur Eat Disord RevApr 10, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Claudia Liu, Cleo Anderson, Mariel Messer et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis used study-level meta-regressions of 31 randomised controlled trials to examine whether baseline eating-disorder severity was associated with the effects and dropout of digital interventions compared with controls. Higher average objective binge eating was associated with larger treatment effects and lower dropout in bivariable analyses; these associations were not retained in multivariable models. Baseline global eating-disorder psychopathology was not associated with effects in bivariable analyses, but was positively associated with effects after adjustment for other study characteristics. The findings suggest that greater baseline severity does not necessarily preclude benefit.

Key findings

  • Higher average objective binge eating was associated with larger treatment effects and lower dropout in bivariable meta-regressions.
  • The objective binge-eating associations were not significant in multivariable meta-regressions.
  • Baseline global psychopathology was unrelated to effects in bivariable analyses but positively associated with effects in the adjusted model.

Why it matters

The findings challenge the assumption that digital interventions are mainly suitable for milder eating-disorder presentations. They suggest that baseline severity may not reliably identify people less likely to benefit or remain engaged, although the differing bivariable and adjusted results warrant cautious interpretation.

What to keep in mind

The analyses were study-level meta-regressions, so associations between average trial characteristics and outcomes may not reflect individual-level relationships. Results also differed between bivariable and multivariable models.

Source

Published in Eur Eat Disord Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.